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INTRODUCTION
•

Obstruction of the Super Vena Cava (SVC) can result
in symptoms, such as facial plethora and swelling.
It can be due to a variety of underlying causes besides
lung malignancies.
The rates of underlying causes have which have
changed over time.
The underlying etiology is used to determine the best

•
•
•

management strategy.

OBJECTIVE
•
•

To discuss the role of etiology in determining the
best initial treatment for SVC syndrome (SVCS).
To outlines a unique management approach for a
patient that represents the changing demographics
of SVCS causes.

CASE PRESENTATION
• A 73-year-old male with end-stage renal disease
(ESRD) and metastatic carcinoma of the colon
presented with swelling of the jaw, neck, and
tongue.
• CT scan showed chronic thrombosis of the SVC and
bilateral brachiocephalic veins.
• He had been receiving hemodialysis and
chemotherapy through central venous catheters
(CVCs) that transversed the SVC and terminated in
the right atrium, resulting in venous stasis.
• Treatment involved double-barrel stent
reconstruction of the SVC with temporary
repositioning of the chemotherapy port catheter and
exchange of the hemodialysis catheter.
• He experienced relief of symptoms and was able to
continue his hemodialysis and chemotherapy
appointments.

DISCUSSION
• For cases of SVCS due to underlying lung malignancies, which has been and
remains the most common cause, endovascular stenting is reserved as a palliative
measure when treatment of a refractory malignancy fails to resolve the obstruction
and for when symptoms are severe because most cases are not life-threatening.
• However, increased use of CVCs has caused a rise in SVCS due to thrombosis, for
which stenting is the first-line treatment. Rare causes of SVCS that may require
surgical correction include mediastinal fibrosis and thymomas.
• Of the few previously published case reports that depict bilateral SVC stenting and
temporary repositioning of a CVC, they all describe cases due to lung malignancies
or mediastinal fibrosis.
• Outlining this case presentation can increase awareness of thrombotic stenosis as
an increasingly common cause of SVCS, which may occur in patients with a
broader range of underlying conditions, ages, and life expectancies and require a
wider array of physicians to be knowledgeable of management strategies.
• While stenting technology has improved dramatically since its inception, follow-up
on stent patency will help determine if expanding treatment for lower acuity cases is
beneficial.
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Figure 1: Etiology and Most Common Treatment Strategy
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Figure 2: Etiology of SVCS change with Time

Figure 4: Patency of SVC following
deployment of bilateral kissing stents
with replaced CVCs

Figure 3: Stenosis of SVC

CONCLUSION
• Endovascular stenting is the treatment of choice for
thrombotic causes of SVCS, which is becoming
more common due to the increased use of CVCs.
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